 |
|
|
| |
Cirrhosis regression based on both Enhanced Liver Fibrosis (ELF) and Fibrotest after Direct-acting Hepatitis C therapeutics corresponds to a lower incidence rate of hepatocellular carcinoma below the cost-effective threshold for surveillance
|
| |
| |
EASL 2021 Presented at The International Liver Congress (EASL), 23-26 June 2021
Winston Dunn MD1, Devin Koestler2, Liyun Ni3, Kathryn Kersey3, Bruce Kreter3, Kyle Hammond3, Anand Chokkalingam3, Diana Brainard3, and Steven A Weinman MD PhD FAASLD1
(1)Internal Medicine, University of Kansas Medical Center, Kansas City, USA, (2)Biostatistics, University of Kansas Medical Center, Kansas City, USA,(3)Gilead Sciences, Inc. Foster City, USA
|
| |
|
|
|
|
|
